Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$27.81 USD

27.81
60,538,186

+0.11 (0.40%)

Updated May 3, 2024 04:00 PM ET

After-Market: $27.81 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims

Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.

Here's Why Pfizer (PFE) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Company News for May 2, 2024

Companies In The News Are: CVS, PFE, PPL, ADP.

Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised

Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.

Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?

On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

Eli Lilly (LLY) Tops Q1 Earnings Estimates

Lilly (LLY) delivered earnings and revenue surprises of 1.98% and 0.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Why Pfizer (PFE) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Tirthankar Chakraborty headshot

What Makes Amazon (AMZN) Attractive Ahead of Q1 Earnings?

Sustained growth in advertising business and acceleration in AWS make Amazon (AMZN) an enticing buy heading into its first-quarter earnings release.

Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.

Sweta Killa headshot

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE) Rises Higher Than Market: Key Facts

Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Why the Market Dipped But Pfizer (PFE) Gained Today

Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.

Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International

UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for UnitedHealth, Pfizer & BlackRock

Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).